This is an announcement that will probably give hope to the 175,000 patients affected in France. A French team has just provided proof that a drug already used to treat type 2 diabetes, lixisenatide, helps slow the progression of Parkinson's disease. Although many researchers around the world have long been trying to unravel the secrets of this neurodegenerative pathology, therapeutic innovations are rare. The results of this new study - just published in the prestigious scientific journal
New
England Journal of Medicine
- are presented as a world first.
“
These results are very positive, because we have been looking for molecules that could have this type of neuroprotective effect for decades ,
”
rejoice Professor Olivier Rascol, neuropharmacologist at Toulouse University Hospital, and Professor Wassilios Meissner, neurologist. at Bordeaux University Hospital, who co-directed the study. As a reminder, Parkinson’s disease is linked to…
This article is reserved for subscribers. You have 85% left to discover.
Do you want to read more?
Unlock all items immediately.
TEST FOR €0.99
Already subscribed? Log in